
Total revenues
 |
$6.2 billion
 |
$5.4 billion
 |
15%
 |
|
Operating earnings, excluding development**
|
$380.3 million |
$302.4 million |
26% |
|
Income from continuing operations
|
$385.6 million |
$389.3 million |
(1)% |
|
Income from discontinued operations***
|
16.1 million |
- - |
|
|
Net income
|
$401.7 million |
$389.3 million |
|
|
Per share results:
|
|
|
|
|
Operating earnings**
|
$0.64 |
$0.63 |
2% |
|
Favorable development of prior-period health care cost estimates
|
- - |
(0.14) |
|
|
Operating earnings, excluding development**
|
$0.64 |
$0.49 |
31% |
|
Income from continuing operations
|
$0.65 |
$0.64 |
2% |
|
Income from discontinued operations***
|
0.03 |
- - |
|
|
Net income |
$0.68 |
$0.64 |
|
* Restated for FAS123R and stock split. Refer to footnote 2 at the end of this press release.
** For a full description of operating earnings and per-share operating earnings, refer to footnote 1 at the end of this press release.
*** Refer to footnote 3 at the end of this press release.
|